Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 22 entries
Sorted by: Best Match Show Resources per page
PCSK9 and carbohydrate metabolism: A double-edged sword.

World journal of diabetes

Filippatos TD, Filippas-Ntekouan S, Pappa E, Panagiotopoulou T, Tsimihodimos V, Elisaf MS.
PMID: 28751953
World J Diabetes. 2017 Jul 15;8(7):311-316. doi: 10.4239/wjd.v8.i7.311.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a paramount role in the degradation of low-density lipoprotein (LDL) receptors (LDLR) on the hepatic cells surface and subsequently affects LDL particles catabolism and LDL cholesterol (LDL-c) levels. The anti-PCSK9 monoclonal antibodies...

Cite
Filippatos TD, Filippas-Ntekouan S, Pappa E, et al. PCSK9 and carbohydrate metabolism: A double-edged sword. World J Diabetes. 2017;8(7):311-316doi: 10.4239/wjd.v8.i7.311.
Filippatos, T. D., Filippas-Ntekouan, S., Pappa, E., Panagiotopoulou, T., Tsimihodimos, V., & Elisaf, M. S. (2017). PCSK9 and carbohydrate metabolism: A double-edged sword. World journal of diabetes, 8(7), 311-316. https://doi.org/10.4239/wjd.v8.i7.311
Filippatos, Theodosios D, et al. "PCSK9 and carbohydrate metabolism: A double-edged sword." World journal of diabetes vol. 8,7 (2017): 311-316. doi: https://doi.org/10.4239/wjd.v8.i7.311
Filippatos TD, Filippas-Ntekouan S, Pappa E, Panagiotopoulou T, Tsimihodimos V, Elisaf MS. PCSK9 and carbohydrate metabolism: A double-edged sword. World J Diabetes. 2017 Jul 15;8(7):311-316. doi: 10.4239/wjd.v8.i7.311. PMID: 28751953; PMCID: PMC5507827.
Copy Download .nbib Format: NLM
LDL receptors and their role in targeted therapy for glioma: a review.

Drug discovery today

Pawar S, Koneru T, McCord E, Tatiparti K, Sau S, Iyer AK.
PMID: 33609780
Drug Discov Today. 2021 May;26(5):1212-1225. doi: 10.1016/j.drudis.2021.02.008. Epub 2021 Feb 18.

Gliomas are highly lethal forms of cancers occurring in the brain. Delivering the drugs into the brain is a major challenge to the treatment of gliomas because of the highly selectively permeable blood-brain barrier (BBB). Tapping the potential of...

Cite
Pawar S, Koneru T, McCord E, et al. LDL receptors and their role in targeted therapy for glioma: a review. Drug Discov Today. 2021;26(5):1212-1225doi: 10.1016/j.drudis.2021.02.008.
Pawar, S., Koneru, T., McCord, E., Tatiparti, K., Sau, S., & Iyer, A. K. (2021). LDL receptors and their role in targeted therapy for glioma: a review. Drug discovery today, 26(5), 1212-1225. https://doi.org/10.1016/j.drudis.2021.02.008
Pawar, Shreya, et al. "LDL receptors and their role in targeted therapy for glioma: a review." Drug discovery today vol. 26,5 (2021): 1212-1225. doi: https://doi.org/10.1016/j.drudis.2021.02.008
Pawar S, Koneru T, McCord E, Tatiparti K, Sau S, Iyer AK. LDL receptors and their role in targeted therapy for glioma: a review. Drug Discov Today. 2021 May;26(5):1212-1225. doi: 10.1016/j.drudis.2021.02.008. Epub 2021 Feb 18. PMID: 33609780.
Copy Download .nbib Format: NLM
PCSK9 and LRP5 in macrophage lipid internalization and inflammation.

Cardiovascular research

Badimon L, Luquero A, Crespo J, Peña E, Borrell-Pages M.
PMID: 32991689
Cardiovasc Res. 2021 Jul 27;117(9):2054-2068. doi: 10.1093/cvr/cvaa254.

AIMS: Atherosclerosis, the leading cause of cardiovascular diseases, is driven by high blood cholesterol levels and chronic inflammation. Low-density lipoprotein receptors (LDLR) play a critical role in regulating blood cholesterol levels by binding to and clearing LDLs from the...

Cite
Badimon L, Luquero A, Crespo J, et al. PCSK9 and LRP5 in macrophage lipid internalization and inflammation. Cardiovasc Res. 2021;117(9):2054-2068doi: 10.1093/cvr/cvaa254.
Badimon, L., Luquero, A., Crespo, J., Peña, E., & Borrell-Pages, M. (2021). PCSK9 and LRP5 in macrophage lipid internalization and inflammation. Cardiovascular research, 117(9), 2054-2068. https://doi.org/10.1093/cvr/cvaa254
Badimon, Lina, et al. "PCSK9 and LRP5 in macrophage lipid internalization and inflammation." Cardiovascular research vol. 117,9 (2021): 2054-2068. doi: https://doi.org/10.1093/cvr/cvaa254
Badimon L, Luquero A, Crespo J, Peña E, Borrell-Pages M. PCSK9 and LRP5 in macrophage lipid internalization and inflammation. Cardiovasc Res. 2021 Jul 27;117(9):2054-2068. doi: 10.1093/cvr/cvaa254. PMID: 32991689.
Copy Download .nbib Format: NLM
Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9.

Journal of lipid research

Oleaga C, Hay J, Gurcan E, David LL, Mueller PA, Tavori H, Shapiro MD, Pamir N, Fazio S.
PMID: 33429337
J Lipid Res. 2021;62:100003. doi: 10.1194/jlr.RA120000964. Epub 2020 Nov 23.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates cholesterol metabolism by inducing the degradation of hepatic low density lipoprotein receptors (LDLRs). Plasma PCSK9 has 2 main molecular forms: a 62 kDa mature form (PCSK9_62) and a 55 kDa, furin-cleaved form...

Cite
Oleaga C, Hay J, Gurcan E, et al. Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9. J Lipid Res. 2020;62:100003doi: 10.1194/jlr.RA120000964.
Oleaga, C., Hay, J., Gurcan, E., David, L. L., Mueller, P. A., Tavori, H., Shapiro, M. D., Pamir, N., & Fazio, S. (2021). Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9. Journal of lipid research, 62100003. https://doi.org/10.1194/jlr.RA120000964
Oleaga, Carlota, et al. "Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9." Journal of lipid research vol. 62 (2021): 100003. doi: https://doi.org/10.1194/jlr.RA120000964
Oleaga C, Hay J, Gurcan E, David LL, Mueller PA, Tavori H, Shapiro MD, Pamir N, Fazio S. Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9. J Lipid Res. 2021;62:100003. doi: 10.1194/jlr.RA120000964. Epub 2020 Nov 23. PMID: 33429337; PMCID: PMC7890205.
Copy Download .nbib Format: NLM
Evaluation of atherosclerotic lesions in cholesterol-fed mice during treatment with paclitaxel in lipid nanoparticles: a magnetic resonance imaging study.

Journal of biomedical research

D Lima A, Hua N, C Maranhão R, A Hamilton J.
PMID: 28808193
J Biomed Res. 2017 Jan 19;31(2):116-121. doi: 10.7555/JBR.31.20160123.

Cholesterol-core nanoparticles (LDE) have been shown to be recognized by low-density lipoprotein receptors (LDLR) after administration; therefore, LDE is an ideal vehicle to deliver drug with targeting property. Paclitaxel, when incorporated into LDE, promotes atherosclerosis regression with reduced drug...

Cite
D Lima A, Hua N, C Maranhão R, et al. Evaluation of atherosclerotic lesions in cholesterol-fed mice during treatment with paclitaxel in lipid nanoparticles: a magnetic resonance imaging study. J Biomed Res. 2017;31(2):116-121doi: 10.7555/JBR.31.20160123.
D Lima, A., Hua, N., C Maranhão, R., & A Hamilton, J. (2017). Evaluation of atherosclerotic lesions in cholesterol-fed mice during treatment with paclitaxel in lipid nanoparticles: a magnetic resonance imaging study. Journal of biomedical research, 31(2), 116-121. https://doi.org/10.7555/JBR.31.20160123
D Lima, Aline, et al. "Evaluation of atherosclerotic lesions in cholesterol-fed mice during treatment with paclitaxel in lipid nanoparticles: a magnetic resonance imaging study." Journal of biomedical research vol. 31,2 (2017): 116-121. doi: https://doi.org/10.7555/JBR.31.20160123
D Lima A, Hua N, C Maranhão R, A Hamilton J. Evaluation of atherosclerotic lesions in cholesterol-fed mice during treatment with paclitaxel in lipid nanoparticles: a magnetic resonance imaging study. J Biomed Res. 2017 Jan 19;31(2):116-121. doi: 10.7555/JBR.31.20160123. PMID: 28808193; PMCID: PMC5445214.
Copy Download .nbib Format: NLM
Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies.

Diseases (Basel, Switzerland)

Ciccarelli G, D'Elia S, De Paulis M, Golino P, Cimmino G.
PMID: 29562587
Diseases. 2018 Mar 17;6(1). doi: 10.3390/diseases6010022.

The role of low-density lipoproteins (LDLs) as a major risk factor for cardiovascular disease has been demonstrated by several epidemiological studies. The molecular basis for LDLs in atherosclerotic plaque formation and progression is not completely unraveled yet. Pharmacological modulation...

Cite
Ciccarelli G, D'Elia S, De Paulis M, et al. Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies. Diseases. 2018;6(1)doi: 10.3390/diseases6010022.
Ciccarelli, G., D'Elia, S., De Paulis, M., Golino, P., & Cimmino, G. (2018). Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies. Diseases (Basel, Switzerland), 6(1), . https://doi.org/10.3390/diseases6010022
Ciccarelli, Giovanni, et al. "Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies." Diseases (Basel, Switzerland) vol. 6,1 (2018). doi: https://doi.org/10.3390/diseases6010022
Ciccarelli G, D'Elia S, De Paulis M, Golino P, Cimmino G. Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies. Diseases. 2018 Mar 17;6(1). doi: 10.3390/diseases6010022. PMID: 29562587; PMCID: PMC5871968.
Copy Download .nbib Format: NLM
Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity.

PloS one

Deshycka R, Sudaryo V, Huang NJ, Xie Y, Smeding LY, Choi MK, Ploegh HL, Lodish HF, Pishesha N.
PMID: 34731223
PLoS One. 2021 Nov 03;16(11):e0259353. doi: 10.1371/journal.pone.0259353. eCollection 2021.

Low plasma levels of Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) are associated with decreased low-density lipoprotein (LDL) cholesterol and a reduced risk of cardiovascular disease. PCSK9 binds to the epidermal growth factor-like repeat A (EGFA) domain of LDL receptors (LDLR),...

Cite
Deshycka R, Sudaryo V, Huang NJ, et al. Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity. PLoS One. 2021;16(11):e0259353doi: 10.1371/journal.pone.0259353.
Deshycka, R., Sudaryo, V., Huang, N. J., Xie, Y., Smeding, L. Y., Choi, M. K., Ploegh, H. L., Lodish, H. F., & Pishesha, N. (2021). Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity. PloS one, 16(11), e0259353. https://doi.org/10.1371/journal.pone.0259353
Deshycka, Rhogerry, et al. "Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity." PloS one vol. 16,11 (2021): e0259353. doi: https://doi.org/10.1371/journal.pone.0259353
Deshycka R, Sudaryo V, Huang NJ, Xie Y, Smeding LY, Choi MK, Ploegh HL, Lodish HF, Pishesha N. Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity. PLoS One. 2021 Nov 03;16(11):e0259353. doi: 10.1371/journal.pone.0259353. eCollection 2021. PMID: 34731223; PMCID: PMC8565730.
Copy Download .nbib Format: NLM
Circulating levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with monocyte subsets in patients with stable coronary artery disease.

Journal of clinical lipidology

Krychtiuk KA, Lenz M, Hohensinner P, Distelmaier K, Schrutka L, Kastl SP, Huber K, Dostal E, Oravec S, Hengstenberg C, Wojta J, Speidl WS.
PMID: 33789832
J Clin Lipidol. 2021 May-Jun;15(3):512-521. doi: 10.1016/j.jacl.2021.02.005. Epub 2021 Mar 16.

BACKGROUND: Proprotein convertase subtilisin/kexin type-9 (PCSK9) is an enzyme promoting the degradation of low-density lipoprotein receptors (LDL-R) in hepatocytes. Inhibition of PCSK9 has emerged as a novel target for lipid-lowering therapy. Monocytes are crucially involved in the pathogenesis of...

Cite
Krychtiuk KA, Lenz M, Hohensinner P, et al. Circulating levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with monocyte subsets in patients with stable coronary artery disease. J Clin Lipidol. 2021;15(3):512-521doi: 10.1016/j.jacl.2021.02.005.
Krychtiuk, K. A., Lenz, M., Hohensinner, P., Distelmaier, K., Schrutka, L., Kastl, S. P., Huber, K., Dostal, E., Oravec, S., Hengstenberg, C., Wojta, J., & Speidl, W. S. (2021). Circulating levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with monocyte subsets in patients with stable coronary artery disease. Journal of clinical lipidology, 15(3), 512-521. https://doi.org/10.1016/j.jacl.2021.02.005
Krychtiuk, Konstantin A, et al. "Circulating levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with monocyte subsets in patients with stable coronary artery disease." Journal of clinical lipidology vol. 15,3 (2021): 512-521. doi: https://doi.org/10.1016/j.jacl.2021.02.005
Krychtiuk KA, Lenz M, Hohensinner P, Distelmaier K, Schrutka L, Kastl SP, Huber K, Dostal E, Oravec S, Hengstenberg C, Wojta J, Speidl WS. Circulating levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with monocyte subsets in patients with stable coronary artery disease. J Clin Lipidol. 2021 May-Jun;15(3):512-521. doi: 10.1016/j.jacl.2021.02.005. Epub 2021 Mar 16. PMID: 33789832.
Copy Download .nbib Format: NLM
Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9.

Journal of lipid research

Oleaga C, Hay J, Gurcan E, David LL, Mueller PA, Tavori H, Shapiro MD, Pamir N, Fazio S.
PMID: 33429337
J Lipid Res. 2020 Nov 23;62:100003. doi: 10.1194/jlr.RA120000964. Epub 2020 Nov 23.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates cholesterol metabolism by inducing the degradation of hepatic low density lipoprotein receptors (LDLRs). Plasma PCSK9 has 2 main molecular forms: a 62 kDa mature form (PCSK9_62) and a 55 kDa, furin-cleaved form...

Cite
Oleaga C, Hay J, Gurcan E, et al. Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9. J Lipid Res. 2020;62:100003doi: 10.1194/jlr.RA120000964.
Oleaga, C., Hay, J., Gurcan, E., David, L. L., Mueller, P. A., Tavori, H., Shapiro, M. D., Pamir, N., & Fazio, S. (2020). Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9. Journal of lipid research, 62100003. https://doi.org/10.1194/jlr.RA120000964
Oleaga, Carlota, et al. "Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9." Journal of lipid research vol. 62 (2020): 100003. doi: https://doi.org/10.1194/jlr.RA120000964
Oleaga C, Hay J, Gurcan E, David LL, Mueller PA, Tavori H, Shapiro MD, Pamir N, Fazio S. Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9. J Lipid Res. 2020 Nov 23;62:100003. doi: 10.1194/jlr.RA120000964. Epub 2020 Nov 23. PMID: 33429337; PMCID: PMC7890205.
Copy Download .nbib Format: NLM
[No title available]

Artificial cells, nanomedicine, and biotechnology

Navarro Chica CE, Qin T, de Haan BJ, Faas MM, Smink AM, Sierra L, López BL, de Vos P.
PMID: 34751061
Artif Cells Nanomed Biotechnol. 2021 Dec;49(1):651-661. doi: 10.1080/21691401.2021.1999968.

Gusperimus is an anti-inflammatory drug that has shown to be effective in managing autoimmunity and preventing graft rejection. This is unstable and easily broken down into cytotoxic components. We encapsulated gusperimus binding it covalently to squalene obtaining squalene-gusperimus nanoparticles...

Cite
Navarro Chica CE, Qin T, de Haan BJ, et al. . Artif Cells Nanomed Biotechnol. 2021;49(1):651-661doi: 10.1080/21691401.2021.1999968.
Navarro Chica, C. E., Qin, T., de Haan, B. J., Faas, M. M., Smink, A. M., Sierra, L., López, B. L., & de Vos, P. (2021). . Artificial cells, nanomedicine, and biotechnology, 49(1), 651-661. https://doi.org/10.1080/21691401.2021.1999968
Navarro Chica, Carlos E, et al. "." Artificial cells, nanomedicine, and biotechnology vol. 49,1 (2021): 651-661. doi: https://doi.org/10.1080/21691401.2021.1999968
Navarro Chica CE, Qin T, de Haan BJ, Faas MM, Smink AM, Sierra L, López BL, de Vos P. . Artif Cells Nanomed Biotechnol. 2021 Dec;49(1):651-661. doi: 10.1080/21691401.2021.1999968. PMID: 34751061.
Copy Download .nbib Format: NLM
Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface-expression of LDLR and CD36 and NLRP3 inflammasome.

Physiological reports

Cyr Y, Lamantia V, Bissonnette S, Burnette M, Besse-Patin A, Demers A, Wabitsch M, Chrétien M, Mayer G, Estall JL, Saleh M, Faraj M.
PMID: 33527668
Physiol Rep. 2021 Feb;9(3):e14721. doi: 10.14814/phy2.14721.

BACKGROUND: LDL-cholesterol lowering variants that upregulate receptor uptake of LDL, such as in PCSK9 and HMGCR, are associated with diabetes via unclear mechanisms. Activation of the NLRP3 inflammasome/interleukin-1 beta (IL-1β) pathway promotes white adipose tissue (WAT) dysfunction and type...

Cite
Cyr Y, Lamantia V, Bissonnette S, et al. Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface-expression of LDLR and CD36 and NLRP3 inflammasome. Physiol Rep. 2021;9(3):e14721doi: 10.14814/phy2.14721.
Cyr, Y., Lamantia, V., Bissonnette, S., Burnette, M., Besse-Patin, A., Demers, A., Wabitsch, M., Chrétien, M., Mayer, G., Estall, J. L., Saleh, M., & Faraj, M. (2021). Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface-expression of LDLR and CD36 and NLRP3 inflammasome. Physiological reports, 9(3), e14721. https://doi.org/10.14814/phy2.14721
Cyr, Yannick, et al. "Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface-expression of LDLR and CD36 and NLRP3 inflammasome." Physiological reports vol. 9,3 (2021): e14721. doi: https://doi.org/10.14814/phy2.14721
Cyr Y, Lamantia V, Bissonnette S, Burnette M, Besse-Patin A, Demers A, Wabitsch M, Chrétien M, Mayer G, Estall JL, Saleh M, Faraj M. Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface-expression of LDLR and CD36 and NLRP3 inflammasome. Physiol Rep. 2021 Feb;9(3):e14721. doi: 10.14814/phy2.14721. PMID: 33527668; PMCID: PMC7851436.
Copy Download .nbib Format: NLM
Common and rare gene variants affecting plasma LDL cholesterol.

The Clinical biochemist. Reviews

Burnett JR, Hooper AJ.
PMID: 18566665
Clin Biochem Rev. 2008 Feb;29(1):11-26.

The plasma level of LDL cholesterol is clinically important and genetically complex. LDL cholesterol levels are in large part determined by the activity of LDL receptors (LDLR) in the liver. Autosomal dominant familial hypercholesterolaemia (FH) - with its high...

Cite
Burnett JR, Hooper AJ. Common and rare gene variants affecting plasma LDL cholesterol. Clin Biochem Rev. 2008;29(1):11-26
Burnett, J. R., & Hooper, A. J. (2008). Common and rare gene variants affecting plasma LDL cholesterol. The Clinical biochemist. Reviews, 29(1), 11-26.
Burnett, John R, and Hooper, Amanda J. "Common and rare gene variants affecting plasma LDL cholesterol." The Clinical biochemist. Reviews vol. 29,1 (2008): 11-26.
Burnett JR, Hooper AJ. Common and rare gene variants affecting plasma LDL cholesterol. Clin Biochem Rev. 2008 Feb;29(1):11-26. PMID: 18566665; PMCID: PMC2423314.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 22 entries